Posted by Michael Wonder on 07 Apr 2017
Institute for Clinical and Economic Review's final report on treatments for rheumatoid arthritis finds evidence inadequate to distinguish overall benefits between newer agents and prices too high in relationship to the clinical value provided to patients
7 April 2017 - Final report and meeting summary reviews evidence on 11 targeted immune modulator drugs, including two currently under FDA review: sarilumab and baricitinib; highlights actions for payers, manufacturers, clinical societies, and other stakeholders to improve patient care while controlling costs.
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report and Meeting Summary assessing the comparative clinical effectiveness and value of targeted immune modulators (TIMs) for treatment of moderately-to-severely active rheumatoid arthritis. TIMs were evaluated alone or in combination with conventional disease-modifying anti-rheumatic drugs, as compared head-to-head or to conventional DMARDs alone.
The review includes 11 TIMs, including two agents currently under regulatory review: the IL-6 inhibitor sarilumab (Kevzara, Sanofi and Regeneron) and the JAK inhibitor baricitinib (Olumiant, Eli Lilly).
